Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...
Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026. Kim ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback